Leading The Way In Pediatric Endo-Cannabinoid Medicine
Phyto Therapeutic Medicine for Inflammatory Conditions
Initial 2.2 Million Square Feet of Cultivation
Exclusive Clinically Validated Formulations
Innovation in Skin Care and Anti-Aging Systems
Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients
by Ruiyang Liu | July 10, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which...Relevium’s CEO Issues Letter of Clarification to Shareholders
by Ruiyang Liu | July 3, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 03, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the...Relevium Issues Statement Regarding Recent Promotional Activity
by Ruiyang Liu | July 1, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 01, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent...Relevium Technologies
Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.contact us
Relevium Technologies Inc.
1000 Sherbrooke West, Suite 2700
Montreal, QC, H3A 3G4
(888) 528-8687
www.releviumtechnologies.com
info@releviumtechnologies.com
trading information
Market data is delayed by 15 minutes
Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients
by Ruiyang Liu | July 10, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which...Relevium’s CEO Issues Letter of Clarification to Shareholders
by Ruiyang Liu | July 3, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 03, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the...Relevium Issues Statement Regarding Recent Promotional Activity
by Ruiyang Liu | July 1, 2019 | 2019 Press Releases | 0 Comments
MONTREAL, July 01, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent...